- Home
- Cardiology
- BaxHTN Phase 3 Trial Evaluating Baxdrostat for Resistant and Uncontrolled Hypertension Management

1w3 min read
Medical Article
Introduction: Hypertension remains a leading cause of cardiovascular morbidity and mortality worldwide, with resistant hypertension (rHTN) and uncontrolled hypertension (uHTN) representing the most challenging subgroups to manage (1). Despite the availability of multiple classes of antihypertensive drugs, a significant proportion of patients contin

BaxHTN Phase 3 Trial Evaluating Baxdrostat for Resistant and Uncontrolled Hypertension Management
Similar Content

Complicated case of Osteoarthritis
1850 Reached2 Comments3 Likes

Acute Renal Failure in Child Due to High Dose of Indomethacin
685 Reached6 Comments

Woman presented with Fever of Unknown Origin
7724 Reached93 Comments19 Likes

Fremanezumab for Prevention and Treatment of Migraine
390 Reached13 Comments11 Likes

Case of Pulmonary Embolism with Syncope
544 Reached4 Likes